PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | 2023-07-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 19 | 20 | 15 | 13 | 15 | 16 | 21 | 33 | 50 | 61 | 73 | 75 | |||||
Marketable Securities Current | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | |||||
Dividends Receivable | 0 | - | - | - | 0 | - | - | - | - | - | - | - | |||||
Other Assets | |||||||||||||||||
Accounts And Notes Receivable Net | - | - | - | - | - | 3 | - | - | - | - | - | - | |||||
Prepaid Expense And Other Assets Current | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Current | 37 | 21 | 23 | 19 | 22 | 17 | 21 | 33 | 50 | 62 | 74 | 75 | |||||
Equity Method Investments | - | - | - | - | - | - | - | - | 0 | 2 | 2 | 2 | |||||
Other Assets Noncurrent | |||||||||||||||||
Intangible Assets Net Excluding Goodwill | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 4 | |||||
Investments And Other Noncurrent Assets | - | 22 | 21 | 20 | 22 | 19 | 25 | 29 | 0 | - | - | - | |||||
Other Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Investments | 0 | - | - | - | 22 | - | - | - | - | - | - | - | |||||
Other Assets Noncurrent | 0 | - | - | - | 0 | - | - | - | - | - | - | - | |||||
Assets Noncurrent | 9 | 35 | 33 | 26 | 33 | 27 | 34 | 37 | 9 | 10 | 5 | 5 | |||||
Assets | 47 | 56 | 56 | 45 | 55 | 44 | 55 | 70 | 60 | 71 | 79 | 80 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | |||||
Accrued Liabilities Current | 1 | 0 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
Dividends Payable Current | 0 | 0 | 0 | - | 0 | 0 | 4 | 6 | 6 | 6 | 4 | 0 | |||||
Liabilities Current | 1 | 2 | 2 | 1 | 3 | 1 | 5 | 7 | 7 | 8 | 5 | 2 | |||||
Other Accrued Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | - | - | |||||
Derivative Liabilities Noncurrent | 1 | 1 | 2 | - | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 3 | |||||
Other Liabilities | 11 | 15 | 18 | 0 | 0 | 2 | 7 | 10 | 13 | 15 | 16 | - | |||||
Liabilities | 12 | 16 | 19 | 2 | 3 | 4 | 12 | 17 | 20 | 22 | 21 | 20 | |||||
Stockholders Equity | |||||||||||||||||
Preferred Stock Value | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 183 | 183 | 181 | 182 | 181 | 181 | 181 | 183 | 185 | 189 | 194 | 199 | |||||
Retained Earnings Accumulated Deficit | -104 | -100 | -101 | -93 | -85 | -97 | -94 | -92 | -116 | -117 | -116 | -119 | |||||
Treasury Stock Common Value | -45 | -45 | -45 | -45 | -45 | -44 | -44 | -43 | -42 | -41 | -40 | -40 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |||||
Stockholders Equity | 33 | 38 | 35 | 44 | 52 | 40 | 43 | 48 | 28 | 31 | 37 | 39 | |||||
Liabilities And Stockholders Equity | 47 | 56 | 56 | 45 | 55 | 44 | 55 | 70 | 60 | 71 | 79 | 80 | |||||
Preferred Stock Shares Authorized | 10 | 10 | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | |||||
Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | 0 | - | |||||
Common Stock Shares Authorized | 200 | 200 | - | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 133 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Issued | 26 | 26 | - | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | |||||
Shares Outstanding | 11 | 11 | - | 7 | 7 | 7 | 7 | 8 | 8 | 9 | 9 | 9 | |||||
Treasury Stock Common Shares | 15 | - | - | - | 15 | 15 | 15 | 14 | 14 | 13 | 13 | 13 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.91% | -17.28% | 18.45% | 4.93% | -11.77% | -10.37% | -5.35% | 9.54% | 1.45% | - | - | - |
| 2025 | -7.98% | -4.21% | -12.77% | -4.65% | -6.69% | 2.56% | -22.15% | -29.75% | -35.44% | 7.44% | 18.74% | 6.18% |
| 2024 | -16.06% | -12.85% | -11.65% | 0.00% | 3.72% | -3.26% | 10.95% | 7.21% | 7.96% | -14.05% | -4.32% | -1.08% |
| 2023 | - | - | - | - | - | - | - | - | - | -9.91% | -12.78% | -22.18% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | 2023-07-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 45.28 | 12.33 | 14.60 | 18.01 | 7.68 | 14.20 | 4.47 | 4.40 | 6.80 | 8.16 | 14.08 | 49.24 | |||||
| Quick Ratio | 45.16 | 12.24 | 14.28 | 17.79 | 7.60 | 14.03 | 4.36 | 4.37 | 6.76 | 8.12 | 14.01 | 49.18 | |||||
| Working Capital | 36.59M | 19.02M | 21.44M | 18.05M | 19.46M | 15.77M | 16.56M | 25.40M | 43.02M | 53.97M | 68.51M | 73.23M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.35 | 0.43 | 0.55 | 0.03 | 0.06 | 0.09 | 0.27 | 0.36 | 0.74 | 0.72 | 0.57 | 0.52 | |||||
| Debt Ratio | 0.25 | 0.29 | 0.35 | 0.03 | 0.06 | 0.08 | 0.21 | 0.24 | 0.34 | 0.31 | 0.26 | 0.26 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -2.32 | -0.98 | -1.90 | -1.24 | 3.19 | 0.69 | 0.94 | 1.65 | -1.80 | -0.55 | -0.56 | -0.76 | |||||
| Free Cash Flow Per Share TTM | -0.62 | -0.52 | -0.67 | -0.68 | -0.41 | -0.33 | -0.25 | -0.36 | -0.22 | -0.24 | -0.28 | -0.19 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | -183.15% | -289.91% | -278.61% | -164.97% | -235.53% | -201.13% | -247.88% | -235.75% | 299.38% | -15.70% | -13.85% | 100.60% | |||||
| EPS Growth (1Y) | -172.74% | -242.69% | -300.72% | -175.20% | -277.16% | -225.06% | -269.73% | -317.47% | 712.40% | 86.05% | 102.33% | 231.57% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -0.31 | -0.83 | -0.49 | -0.82 | 0.39 | 2.33 | 1.92 | 1.19 | -1.18 | -3.98 | -3.81 | -3.51 | |||||
| P/B TTM | 0.18 | 0.20 | 0.18 | 0.16 | 0.18 | 0.28 | 0.32 | 0.32 | 0.73 | 0.60 | 0.51 | 0.86 | |||||
| Market Cap | 6.05M | 7.59M | 6.32M | 6.93M | 9.09M | 11.17M | 13.82M | 15.42M | 20.31M | 18.85M | 18.58M | 33.52M | |||||
| Enterprise Value | -12.55M | -12.58M | -9.09M | -6.25M | -6.08M | -5.21M | -7.02M | -17.22M | -29.87M | -42.36M | -54.84M | -41.14M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -5.15M | -4.80M | -4.52M | -4.60M | -2.98M | -2.27M | -1.94M | -2.87M | -2.15M | -2.11M | -2.47M | -2.37M | |||||
| Net Debt | -18.60M | -20.17M | -15.41M | -13.18M | -15.17M | -16.38M | -20.84M | -32.64M | -50.18M | -61.21M | -73.43M | -74.66M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| PEG Ratio | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| EV Revenue TTM | |||||||||||||||||
| EV FCF TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
PharmaCyte Biotech, Inc. (PMCB) — SEC Financial Statements & Analysis
PharmaCyte Biotech, Inc. (PMCB) is a biological products, (no diagnostic substances) company, incorporated in NV. PharmaCyte Biotech, Inc. trades on Nasdaq as: PMCB. Based on its latest SEC filing (Form 10-Q, period ending 2026-04-30), PharmaCyte Biotech, Inc. reported a Debt-to-Equity ratio of 0.35x, a Price-to-Book (P/B) ratio of 0.18x (TTM), at a market cap of $6.05M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.35x
- P/B TTM
- 0.18x
- Market Cap
- $6.05M
Data as of 2026-04-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is PharmaCyte Biotech, Inc. in?
PharmaCyte Biotech, Inc. (PMCB) operates in the Biological Products, (No Diagnostic Substances) industry.
What is PMCB's market cap?
PharmaCyte Biotech, Inc. (PMCB) has a market capitalization of $6.05M as of 2026-04-30.
What exchange does PMCB trade on?
PharmaCyte Biotech, Inc. (PMCB) trades on the Nasdaq.
Where is PharmaCyte Biotech, Inc. incorporated?
PharmaCyte Biotech, Inc. is incorporated in NV.